CHMP recommends EU approval of Inlyta (Pfizer) for Renal Cell Carcinoma

The EMA's CHMP has recommended the marketing authorisation of Inlyta (axitinib), from Pfizer, for the treatment of adult patients with advanced Renal Cell Carcinoma, after failure of prior treatment with sunitinib or a cytokine. This drug therapy is designed to selectively inhibit tyrosine kinases, including vascular endothelial growth factor (VEGF) receptors 1, 2 and 3, which can influence tumour growth, vascular angiogenesis and progression of cancer. The CHMP's positive opinion will be reviewed by the European Commission in the coming months.